dc.contributor.author | Kılıç, Aylin | |
dc.contributor.author | Özpınar, Ayşe | |
dc.contributor.author | Tanrıverdi, Cafer | |
dc.date.accessioned | 2023-09-08T07:35:24Z | |
dc.date.available | 2023-09-08T07:35:24Z | |
dc.date.issued | 2023 | en_US |
dc.identifier.citation | Kılıç, A., Özpınar, A. ve Tanrıverdi, C. (2023). Comparison of visual outcomes of two trifocal IOLs. Journal of Refractive Surgery, 39(8), 524-530. https://dx.doi.org/10.3928/1081597X-20230424-01 | en_US |
dc.identifier.issn | 1081-597X | |
dc.identifier.issn | 1938-2391 | |
dc.identifier.uri | https://dx.doi.org/10.3928/1081597X-20230424-01 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/11395 | |
dc.description.abstract | PURPOSE:To compare the visual outcomes of bilateral im-plantation of two commercially available trifocal intraocular lenses (IOLs) (AcrySof IQ PanOptix IOL; Alcon Laboratories, Inc and AcrivaUD Trinova IOL; VSY Biotechnology). METHODS:This comparative, investigator-initiated, single-center randomized trial was conducted by the Department of Ophthal-mology of the Medipol Mega University Hospital in Istanbul, Tur-key. Adult patients were randomized in a 1:1 ratio using a block randomization program to undergo cataract surgery and receive the implantation of either the PanOptix or Trinova IOL in both eyes. Outcome measures including binocular uncorrected and cor-rected visual acuities at distance, intermediate (66 cm), and near (40 cm), defocus curve, refractive outcomes, contrast sensitivity, glare and halos, and patient satisfaction were assessed at a mini-mum of 3 months following bilateral IOL implantation. RESULTS:A total of 71 patients (142 eyes) were included, with 35 patients (70 eyes) in the PanOptix IOL group and 36 patients (72 eyes) in the Trinova IOL group. At the 3-month follow-up examination, mean distance-corrected intermedi-ate visual acuity (primary endpoint) was significantly better for the PanOptix IOL group (0.0 & PLUSMN; 0.09 logMAR) compared with the Trinova IOL group (0.01 & PLUSMN; 0.10 logMAR) (P = .0304). Mean logMAR uncorrected intermediate acuity (UIVA) and near (UNVA) visual acuity were also significantly better for the PanOptix IOL group (UIVA = 0.1 & PLUSMN; 0.10 logMAR; UNVA= 0.0 & PLUSMN; 0.09 logMAR) compared with the Trinova IOL group (UIVA = 0.2 & PLUSMN; 0.10 logMAR; UNVA = 0.2 & PLUSMN; 0.11 logMAR) (both P < .001). There were no statistically significant differences in all other outcomes between groups. No adverse events were reported in both groups. CONCLUSIONS:These results suggest that the PanOptix IOL provides better intermediate and near visual outcomes com-pared to the Trinova IOL and represents a good choice for pa-tients seeking to achieve spectacle independence. | en_US |
dc.description.sponsorship | Alcon Laboratories, Inc | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Slack Incorporated | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | IOLs | en_US |
dc.subject | Visual Outcomes | en_US |
dc.subject | Ophthalmology | en_US |
dc.title | Comparison of visual outcomes of two trifocal IOLs | en_US |
dc.type | article | en_US |
dc.relation.ispartof | Journal of Refractive Surgery | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Göz Hastalıkları Ana Bilim Dalı | en_US |
dc.authorid | 0000-0001-8880-0026 | en_US |
dc.authorid | 0000-0003-4373-7400 | en_US |
dc.authorid | 0000-0003-2445-6339 | en_US |
dc.identifier.volume | 39 | en_US |
dc.identifier.issue | 8 | en_US |
dc.identifier.startpage | 524 | en_US |
dc.identifier.endpage | 530 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.3928/1081597X-20230424-01 | en_US |
dc.institutionauthor | Kılıç, Aylin | |
dc.institutionauthor | Özpınar, Ayşe | |
dc.institutionauthor | Tanrıverdi, Cafer | |
dc.identifier.wosquality | Q2 | en_US |
dc.identifier.wos | 001051410300004 | en_US |
dc.identifier.scopus | 2-s2.0-85168932912 | en_US |
dc.identifier.pmid | 37578176 | en_US |
dc.identifier.scopusquality | Q2 | en_US |